US FDA Orders New Vision Loss Warning for Ozempic, Wegovy, and Mounjaro
Summarized by AI; it may make mistakes. Check important info
Summarized by AI; it may make mistakes. Check important info
American health regulators have mandated an updated safety warning for popular weight-loss and diabetes medications, including Ozempic and Wegovy, following findings linked to a rare condition that causes severe and potentially permanent sight impairment.
The US Food and Drug Administration (FDA) directed manufacturers to update product labels across the entire class of glucagon-like peptide-1 (GLP-1) receptor agonist drugs. These medicines are widely prescribed across the globe to manage type 2 diabetes, obesity, and associated medical conditions.
Optic Nerve Risk Triggers Regulatory Action
The regulatory update targets non-arteritic anterior ischemic optic neuropathy (NAION), a medical condition stemming from restricted blood flow to the optic nerve. The disorder triggers sudden vision loss and can leave patients with permanent eye damage.
The safety directive impacts high-demand blockbusters, including Novo Nordisk’s Ozempic and Wegovy, alongside Eli Lilly’s Mounjaro and Zepbound.
Regulatory scrutiny intensified after a 2024 medical study highlighted potential links between semaglutide—the primary active ingredient in Ozempic and Wegovy—and NAION development.
Clinical Trial Data Reveals Increased Incidence
An extensive FDA analysis spanning over 125 clinical trials demonstrated that NAION occurred in approximately six out of every 100,000 patients who took a GLP-1 drug for a minimum of 12 months.
In contrast, trial participants receiving placebos or alternative glucose-lowering therapies recorded an incidence rate below four cases per 100,000 people.
The federal regulator also tracked reports filed through its official adverse event reporting system, which documents post-market drug side effects and patient safety injuries.
Key Symptoms and Medical Directives
While classifying NAION as a rare event, the FDA advised healthcare professionals and patients to monitor for early warning signals. Primary symptoms include sudden blurred vision, blind spots, altered colour perception, and unexpected visual distortions.
Regulators instructed patients who experience sudden changes in their eyesight while taking GLP-1 medications to consult medical practitioners immediately. The mandatory label update marks a fresh phase of official oversight for the GLP-1 drug category amid unprecedented global demand.
